



ICSGlobal LIMITED

ASX RELEASE – 27 February 2018

First Half-Year Results: Revenue up 12.1 %, Profit up 61.7 %, Interim Dividend of 2.5 cents declared

- H1 2018 underlying profit of \$324,723 up 61.7% on H1 2017.
- H1 2018 sales revenue of \$2,405,687 was up 12% on H1 2017, in GBP revenue terms was up 12% to £1,412,165.
- Payment of an annual dividend of 4 cents per share (\$423,361) for the 2017 year in November 2017.
- The 2018 year interim dividend has been re-instated at 2.5 cents per share as the Board believes MBC will continue to experience solid growth in revenues and profit.
- Maintain 2018 full year guidance of net profit after tax expected to be in the range of \$800,000 to \$ 1.1 million.
- MBC highlights include:
 - Revenue up 12% in GBP terms and profit up 7% in GBP terms
 - On the MBC revenue side, our clinic revenue continues to grow and currently represents 22% of our business. The Major National Hospital Group that we announced at the AGM has commenced in December and is growing every month as reported and we expect this revenue to grow steadily over the next 2 years. One of our 1st clinics that were mainly low margin processing have decided to take this function in house as at the end of March 2018. The revenue and growth from the Major National Hospital Group will more than make up the loss of revenue from this clinic leaving.
 - Expenses in the GBP increased 13% due mainly to increased staff, hosting and IT support costs due to the growth in our clinics segment. In October 2017 we put out to tender our hosting and IT support function and we have appointed our new service providers and we are currently in the process of migrating to our new suppliers. We expect to see yearly savings in excess of £40,000 pounds in the 2018/19 year.
 - The medical indemnity insurance product in Q4 2016 as part of the strategy of providing quality ancillary services to our client base is steadily growing and we are generating incremental recurring revenue for MBC.
 - MBC continued to invest in infrastructure, personnel and IT to grow the Clinic/Hospital division which is incremental business targeting different segments of our market. The increased costs particularly in IT have been incurred as we needed to ensure that the IT platform had no single point of failure and increased speed to meet the demands of this segment and going forward comply with the EU general data protection rules.
 - MBC have appointed a new Financial Accountant in October 2017 to assist the existing management team with stronger financial reporting in a growing business.

H1 2018 result

The Board is pleased to advise that H1 2018 underlying profit of \$ 324,723 up 61.2% puts us back on track for revenue and profit growth. As previously advised at the November 2017 AGM, we are continuing to grow our Clinic/Hospital clients and the signing of a Major National Hospital Group in December 2017 is a strong sign that this sector of our business will continue to grow. For this reason, the board has decided to re-instate an interim dividend.

We are pleased to report H1 2018 sales revenue for MBC in GBP increased 12% to £1,412,165 (\$2,405,687 in AUD up 12% on H1 2017). Profit in GBP terms for MBC increased 7%. Staff costs increased due to training for the new clinic starting in December 2017. The H1 2018 profit includes an FX gain of AUD \$17,599 due to the conversion of the GBP bank account.

The Board expects to see an improved financial performance in H2 2018.



Full financial details of the half-year result can be found in the accompanying Appendix 4D and Interim Report.

ICS Group	6 months to December 2016	6 months to December 2017	Change (%)
	AUD	AUD	
Revenue from Operations	2,145,640	2,405,687	+12.1%
Profit after Tax	200,763	324,723	+61.7%
Profit after Tax UK Business in GBP	£307,090	£327,073	+6.5%
	Balance 30 June 2017	Balance 31 December 2017	Change
	AUD	AUD	%
Cash and Equivalents (excluding UK Doctors' funds)	1,544,714	1,675,734	+8.5%

Dividends

During the half-year, the Board was pleased to be able to pay another ICS dividend of 4.0 cents per share (\$423,361) for the 2017 year.

The 2018 year interim dividend has been re-instated with the record of Tuesday the 13th of March 2018. It will be paid on Thursday the 12th of April 2018.

Guidance

The Board re-affirms its previous 2018 full year guidance of net profit after tax and expects it to be in the range of \$800,000 to \$1.1m for the 2018 year¹.

Cash balance

Cash and equivalents (excluding cash held in the UK on behalf of Doctors) as at 31 December 2017 was \$1,675,734 which was an increase of 8.5 % on the June 2017 reporting balance of \$1,544,714. This cash increase was recorded after a dividend of \$ 423,361 was paid in November 2017 and the balance is attributable to movements in working capital.

UK Operations

MBC has been able to grow revenue by 12% in GBP terms, and profit increased 7% in GBP terms. As mentioned previously, the increased costs are primarily attributable to increased staff costs as our Clinic/Hospital clients are growing.

On the MBC revenue side, a large clinic that was signed up during H1 2018 commenced operations in December 2017. Increased revenue is expected in H2 2018.

The Board is pleased to report that working in conjunction with the MBC management team, the medical indemnity insurance product in Q4 2016 is starting to generate revenues. This is part of the strategy of providing quality ancillary services to our client base which will generate incremental recurring revenue for MBC.

¹ Subject to FX rates. The upper range of guidance includes potential new acquisitions/divestments



MBC continued to invest in infrastructure, personnel and IT to grow the Clinic/Hospital division which is incremental business targeting different segments of our market. The increased costs particularly in IT have been incurred as we needed to ensure that the IT platform had no single point of failure and increased speed to meet the demands of this segment.

We would like to acknowledge the efforts of our UK management team especially our MD Findlay Fyfe and our MBC Chairman Garry Chapman for their ongoing support and continued growth strategies in driving our business.

Australian corporate cash costs

The corporate cash costs in Australia are running around \$460,000 on an annualised basis, including costs that were incurred for the dividend payment. The H1 2018 Australian corporate cash costs were \$235,182.

Future activities

OpenLearning

The Board is pleased to advise that OpenLearning (www.openlearning.com), the Australian based education technology company in which ICS has a \$0.293 million investment for a c. 2.27% stake, has made substantial progress on several fronts.

As a result, the Board continues to assess the ability to monetise its investment in the Australian based education technology company, OpenLearning.

In Q4 2017, as part of a \$10m capital raising over a number of tranches, Open Learning raised \$5m from Prestariang, a leading participant in the ICT industry in SE Asia. The raising was conducted at a pre-money \$25m valuation - over two times the ICS investment price.

Other Opportunities

The Board is constantly looking at a number of acquisitions/investments that are in the healthcare space. The Board will update the market on any progress in relation to these opportunities.

We thank you for your on-going support.

For and on behalf of the Board.

A handwritten signature in black ink, appearing to be 'Kevin Barry', with a large, stylized loop at the end.

Kevin Barry

1. Company details

Name of entity:	ICSGlobal Limited
ABN:	72 073 695 584
Reporting period:	For the half-year ended 31 December 2017
Previous period:	For the half-year ended 31 December 2016

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	12.1% to	2,405,687
Profit from ordinary activities after tax attributable to the owners of ICSGlobal Limited	up	61.7% to	324,723
Profit for the half-year attributable to the owners of ICSGlobal Limited	up	61.7% to	324,723

Dividends

	Amount per security Cents	Franked amount per security Cents
Final dividend for the year ended 30 June 2017 (unfranked) was paid on 9 November 2017	4.000	-

Comments

The profit for the consolidated entity after providing for income tax amounted to \$324,723 (31 December 2016: \$200,763).

Further commentary on the business operations and developments by directors are contained in the attached letter from the Chairman.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>27.57</u>	<u>24.64</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividend reinvestment plans

Not applicable.

7. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

8. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

9. Attachments

Details of attachments (if any):

The Interim Report of ICSGlobal Limited for the half-year ended 31 December 2017 is attached.

10. Signed



Signed _____

Date: 27 February 2018

Kevin Barry
Chairman
Sydney

ICSGlobal Limited

ABN 72 073 695 584

Interim Report - 31 December 2017

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of ICSGlobal Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2017.

Directors

The following persons were directors of ICSGlobal Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Kevin Barry - Chairman
Gregory Quirk
Victor Shkolnik
James Canning-Ure

Principal activities

The principal activities of the consolidated entity during the financial half-year were the operations of an investment holding company in Australia and the provision of medical billing services, specifically in the United Kingdom ('UK').

Review of operations

The profit for the consolidated entity after providing for income tax amounted to \$324,723 (31 December 2016: \$200,763).

Further commentary on the business operations and developments by directors are contained in the attached letter from the Chairman.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Kevin Barry
Chairman

27 February 2018
Sydney

**ICS GLOBAL LIMITED
ABN 72 073 695 584
AND ITS CONTROLLED ENTITIES**

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF ICS GLOBAL LIMITED**

SYDNEY

Level 40
2 Park Street
Sydney NSW 2000
Australia

Ph: (612) 9263 2600
Fx: (612) 9263 2800

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2017 there have been no contraventions of:

- (i) the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

Hall Chadwick

Hall Chadwick
Level 40, 2 Park Street
Sydney NSW 2000

Sandeep Kumar

Sandeep Kumar
Partner
Date: 27 February 2018

A Member of PrimeGlobal
An Association of Independent
Accounting Firms

 **PrimeGlobal**

Statement of profit or loss and other comprehensive income	4
Statement of financial position	5
Statement of changes in equity	6
Statement of cash flows	7
Notes to the financial statements	8
Directors' declaration	13
Independent auditor's review report to the members of ICSGlobal Limited	14

General information

The financial statements cover ICSGlobal Limited as a consolidated entity consisting of ICSGlobal Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is ICSGlobal Limited's functional and presentation currency.

ICSGlobal Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 3.03
20 Bond Street
Sydney, NSW 2000

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2018. The directors have the power to amend and reissue the financial statements.

ICSGlobal Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2017



		Consolidated	
	Note	31/12/2017	31/12/2016
		\$	\$
Revenue	3	2,405,687	2,145,640
Expenses			
Employee benefits expenses		(1,144,102)	(984,542)
External contractor expenses		(54,908)	(67,424)
Directors fees		(90,000)	(70,000)
Occupancy expenses		(123,985)	(118,401)
Depreciation and amortisation expenses		(110,658)	(105,058)
Marketing expenses		(66,997)	(61,744)
Legal fees		(8,722)	(2,668)
Communication and travel		(15,835)	(10,080)
Postage and stationery		(60,186)	(50,018)
Hosting and support		(112,205)	(120,563)
Computer expenses		(20,765)	(22,028)
Net foreign exchange gain/(loss)		17,599	(90,310)
Other expenses		(279,209)	(242,041)
Profit before income tax expense		335,714	200,763
Income tax expense		(10,991)	-
Profit after income tax expense for the half-year attributable to the owners of ICSGlobal Limited		324,723	200,763
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		21,842	(47,986)
Other comprehensive income for the half-year, net of tax		21,842	(47,986)
Total comprehensive income for the half-year attributable to the owners of ICSGlobal Limited		346,565	152,777
		Cents	Cents
Basic earnings per share	12	3.068	1.900
Diluted earnings per share	12	3.011	1.859

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

		Consolidated	
	Note	31/12/2017	30/06/2017
		\$	\$
Assets			
Current assets			
Cash and cash equivalents	4	2,418,268	2,154,326
Trade and other receivables	5	583,962	612,090
Total current assets		<u>3,002,230</u>	<u>2,766,416</u>
Non-current assets			
Available-for-sale financial assets		293,900	293,900
Property, plant and equipment		81,845	75,253
Intangibles	6	2,673,295	2,722,378
Deferred tax		670,471	670,471
Total non-current assets		<u>3,719,511</u>	<u>3,762,002</u>
Total assets		<u>6,721,741</u>	<u>6,528,418</u>
Liabilities			
Current liabilities			
Trade and other payables	7	1,104,132	841,538
Income tax		23,195	11,946
Employee benefits		3,465	18,756
Total current liabilities		<u>1,130,792</u>	<u>872,240</u>
Total liabilities		<u>1,130,792</u>	<u>872,240</u>
Net assets		<u>5,590,949</u>	<u>5,656,178</u>
Equity			
Issued capital	8	34,759,895	34,759,895
Reserves		707,404	673,995
Accumulated losses		(29,876,350)	(29,777,712)
Total equity		<u>5,590,949</u>	<u>5,656,178</u>

The above statement of financial position should be read in conjunction with the accompanying notes

ICSGlobal Limited
Statement of changes in equity
For the half-year ended 31 December 2017



Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2016	34,759,895	715,952	(29,870,379)	5,605,468
Profit after income tax expense for the half-year	-	-	200,763	200,763
Other comprehensive income for the half-year, net of tax	-	(47,986)	-	(47,986)
Total comprehensive income for the half-year	-	(47,986)	200,763	152,777
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	11,202	-	11,202
Dividends paid (note 9)	-	-	(370,441)	(370,441)
Balance at 31 December 2016	<u>34,759,895</u>	<u>679,168</u>	<u>(30,040,057)</u>	<u>5,399,006</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2017	34,759,895	673,995	(29,777,712)	5,656,178
Profit after income tax expense for the half-year	-	-	324,723	324,723
Other comprehensive income for the half-year, net of tax	-	21,842	-	21,842
Total comprehensive income for the half-year	-	21,842	324,723	346,565
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	11,567	-	11,567
Dividends paid (note 9)	-	-	(423,361)	(423,361)
Balance at 31 December 2017	<u>34,759,895</u>	<u>707,404</u>	<u>(29,876,350)</u>	<u>5,590,949</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

Note	Consolidated	
	31/12/2017 \$	31/12/2016 \$
Cash flows from operating activities		
Receipts from customers (inclusive of GST and VAT)	2,901,410	2,678,196
Payments to suppliers and employees (inclusive of GST and VAT)	<u>(2,158,271)</u>	<u>(1,499,040)</u>
	743,139	1,179,156
Interest received	<u>12</u>	<u>78</u>
Net cash from operating activities	<u>743,151</u>	<u>1,179,234</u>
Cash flows from investing activities		
Payments for property, plant and equipment	(32,242)	(7,948)
Payments for intangibles	<u>(23,606)</u>	<u>(139,946)</u>
Net cash used in investing activities	<u>(55,848)</u>	<u>(147,894)</u>
Cash flows from financing activities		
Dividends paid	<u>(423,361)</u>	<u>(370,441)</u>
Net cash used in financing activities	<u>(423,361)</u>	<u>(370,441)</u>
Net increase in cash and cash equivalents	263,942	660,899
Cash and cash equivalents at the beginning of the financial half-year	2,154,326	1,994,535
Effects of exchange rate changes on cash and cash equivalents	<u>-</u>	<u>(24,618)</u>
Cash and cash equivalents at the end of the financial half-year	<u>4</u> <u>2,418,268</u>	<u>2,630,816</u>

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2017 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2017 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the policies stated below.

Comparative figures

Comparative have been realigned where necessary, to agree with current year presentation. There was no change in the profit or net assets.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity during the financial half-year ended 31 December 2017 and are not expected to have any significant impact for the full financial year ending 30 June 2018.

Note 2. Operating segments

Identification of reportable operating segments

The consolidated entity only has one reportable segment being the provision of medical billing services in the UK.

Geographical information

	Sales to external customers		Geographical non-current assets	
	31/12/2017 \$	31/12/2016 \$	31/12/2017 \$	30/06/2017 \$
Australia	-	-	293,900	293,900
United Kingdom	2,338,034	2,066,329	2,755,140	2,797,631
	<u>2,338,034</u>	<u>2,066,329</u>	<u>3,049,040</u>	<u>3,091,531</u>

The geographical non-current assets above are exclusive of, where applicable, financial instruments, deferred tax assets, post-employment benefits assets and rights under insurance contracts.

Note 3. Revenue

	Consolidated 31/12/2017 \$	31/12/2016 \$
<i>Sales revenue</i>		
Medical billing service	2,338,034	2,066,329
<i>Other revenue</i>		
Interest	12	78
Other revenue	67,641	79,233
	<u>67,653</u>	<u>79,311</u>
Revenue	<u><u>2,405,687</u></u>	<u><u>2,145,640</u></u>

Note 4. Current assets - cash and cash equivalents

	Consolidated 31/12/2017 \$	30/06/2017 \$
Cash on trust *	742,534	609,612
Cash at bank	1,675,734	1,544,714
	<u><u>2,418,268</u></u>	<u><u>2,154,326</u></u>

* The cash on trust is offset by an equal liability in other payables and it is not for general use of the consolidated entity.

Note 5. Current assets - trade and other receivables

	Consolidated 31/12/2017 \$	30/06/2017 \$
Trade receivables	506,465	510,969
Less: Provision for impairment of receivables	(34,685)	(34,685)
	<u>471,780</u>	<u>476,284</u>
Other receivables	74,765	73,186
Related party receivables	31,086	51,870
VAT and GST receivable	6,331	10,750
	<u><u>583,962</u></u>	<u><u>612,090</u></u>

Note 6. Non-current assets - intangibles

	Consolidated 31/12/2017 \$	30/06/2017 \$
Goodwill - at cost	2,214,282	2,214,282
Software - at cost	1,208,580	1,159,454
Less: Accumulated amortisation	(749,567)	(651,358)
	<u>459,013</u>	<u>508,096</u>
	<u><u>2,673,295</u></u>	<u><u>2,722,378</u></u>

Note 6. Non-current assets - intangibles (continued)

Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

Consolidated	Goodwill \$	Software \$	Total \$
Balance at 1 July 2017	2,214,282	508,096	2,722,378
Additions	-	23,606	23,606
Exchange differences	-	10,304	10,304
Amortisation expense	-	(82,993)	(82,993)
Balance at 31 December 2017	<u>2,214,282</u>	<u>459,013</u>	<u>2,673,295</u>

Note 7. Current liabilities - trade and other payables

	Consolidated	
	31/12/2017 \$	30/06/2017 \$
Trade payables	164,948	52,436
VAT payable	160,928	141,282
Other payables	778,256	647,820
	<u>1,104,132</u>	<u>841,538</u>

Note 8. Equity - issued capital

	31/12/2017 Shares	Consolidated 30/06/2017 Shares	31/12/2017 \$	30/06/2017 \$
Ordinary shares - fully paid	<u>10,584,019</u>	<u>10,584,019</u>	<u>34,759,895</u>	<u>34,759,895</u>

Performance rights

There were 280,000 (30 June 2017: 200,000) performance rights as at 31 December 2017 which may convert into ordinary shares if the performance conditions are met.

Note 9. Equity - dividends

Dividends paid during the financial half-year were as follows:

	Consolidated	
	31/12/2017 \$	31/12/2016 \$
Final dividend for the year ended 30 June 2017 of 4.0 cents per ordinary share paid unfranked (2016: 3.5 cents per ordinary share unfranked)	<u>423,361</u>	<u>370,441</u>

Note 10. Fair value measurement

Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Consolidated - 31/12/2017				
Assets				
Ordinary shares available-for-sale	-	-	293,900	293,900
Total assets	-	-	293,900	293,900

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Consolidated - 30/06/2017				
Assets				
Ordinary shares available-for-sale	-	-	293,900	293,900
Total assets	-	-	293,900	293,900

There were no transfers between levels during the financial half-year.

Valuation techniques for fair value measurements categorised within level 2 and level 3

Unquoted investments have been valued using a discounted cash flow model.

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value. The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature. The fair value of financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial instruments. They are classified as level 3 fair values in the fair value hierarchy due to the inclusion of unobservable inputs.

Note 11. Contingent liabilities

The consolidated entity had no contingent liabilities at 31 December 2017 and 30 June 2017.

Note 12. Earnings per share

	Consolidated	
	31/12/2017	31/12/2016
	\$	\$
Profit after income tax attributable to the owners of ICSGlobal Limited	<u>324,723</u>	<u>200,763</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	10,584,019	10,564,250
Adjustments for calculation of diluted earnings per share:		
Performance rights	<u>200,000</u>	<u>237,500</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>10,784,019</u>	<u>10,801,750</u>
	Cents	Cents
Basic earnings per share	3.068	1.900
Diluted earnings per share	3.011	1.859

Note 13. Events after the reporting period

No matter or circumstance has arisen since 31 December 2017 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2017 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Kevin Barry
Chairman

27 February 2018
Sydney

**ICS GLOBAL LIMITED
ABN 72 073 695 584
AND ITS CONTROLLED ENTITIES**

**INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
ICS GLOBAL LIMITED**

SYDNEY

Level 40
2 Park Street
Sydney NSW 2000
Australia
Ph: (612) 9263 2600
Fx: (612) 9263 2800

Report on the Interim Financial Report

We have reviewed the accompanying interim financial report of ICS Global Limited, which comprises the consolidated statement of financial position as at 31 December 2017, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity, and consolidated statement of cash flows for the half year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information and the directors' declaration.

Directors' Responsibility for the Interim Financial Report

The directors of ICS Global Limited are responsible for the preparation of the half year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the interim financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the interim financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of ICS Global Limited's financial position as at 31 December 2017 and its performance for the period ended on that date, and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of ICS Global Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of an half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

A Member of PrimeGlobal
An Association of Independent
Accounting Firms



A member of AGN
International Ltd, a
worldwide association
of separate and
independent
accounting
and consulting firms

ICS GLOBAL LIMITED
ABN 72 073 695 584
AND ITS CONTROLLED ENTITIES

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
ICS GLOBAL LIMITED

SYDNEY

Level 40
2 Park Street
Sydney NSW 2000
Australia
Ph: (612) 9263 2600
Fx: (612) 9263 2800

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half year financial report of ICS Global Limited is not in accordance with the Corporations Act 2001 including:

- (i) giving a true and fair view of ICS Global Limited's financial position as at 31 December 2017 and of its performance for the half year ended on that date; and
- (ii) complying with AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

Hall Chadwick

HALL CHADWICK
Level 40, 2 Park Street
Sydney NSW 2000

Sandeep Kumar

Sandeep Kumar

Partner

Date: 27 February 2018

A Member of PrimeGlobal
An Association of Independent
Accounting Firms

 **PrimeGlobal**